the market?
ImmunoGen
NASDAQ: IMGN
17.89
0.15
(0.85%)
| Today's Open | $17.68 |
|---|---|
| Previous Close | $17.74 |
| Daily Range | $17.40 - $18.48 |
| 52-Week Range | $10.85 - $18.48 |
| Market Cap | $1.5B |
| P/E Ratio | -19.71 |
| Dividend (Yield) | $0.00 (0.0%) |
| Volume | 1,076,192 |
| Average Daily Volume | 821,461 |
| Current FY EPS | -$0.90 |
How do you think IMGN
will perform against the market?
Top IMGN Bull/Bear Pitches
TMFBreakerThiel (< 20)
Submitted
September 28, 2010
Hammered because it failed to get an accelerated review from FDA on T-DM1. Does complicate things, but doesn't bear on the efficacy of the drug, which looks strong in HER-2 pos breast cancer that has … More
NetscribeHealthC (< 20)
Submitted
February 14, 2007
ImmunoGen develops therapeutics for the treatment of cancer. The company’s tumor-activated prodrug (TAP) technology uses antibodies to deliver a potent cytotoxic agent specifically to treat cancer cel … More
News & Commentary
Angelina Jolie's Selfless Act Heightens Breast Cancer Awareness
Jolie's personal experiences brings the dangers of breast cancer into new light and also gives hope to current and future breast cancer sufferers thanks to improving therapies and diagnostic tests.ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2013 Financial Results and Provides Quarterly Upda
ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2013 Financial Re
Market Wrap for Friday, April 12: Stocks Record Modest Losses; Treasuries Surge and Precious Metals
Market Wrap for Friday, April 12: Stocks Record Modest Losses; Treasuries Surge and Precious Metals PlungeA "Breakthrough" May Be on the Way for Breast Cancer Patients
A new Food and Drug Administration designation coupled with a 248% improvement progression-free survival over the current standard of treatment could have this drug well on its way to approval.Sector
Healthcare
Industry
Drugs
ImmunoGen (IMGN) Description
ImmunoGen develops cancer therapeutics through its tumor-activated, prodrug technology, which targets antibodies with cancer-killing drugs. Website: http://www.immunogen.com/
CEO Rating by Glassdoor
More details for ImmunoGen Jobs
ImmunoGen reviews from employees
